Sugi Predict

Sugi Predict / Compounds / SCHEMBL1103331

SCHEMBL1103331

SCHEMBL1103331

Cn1c2ccccc2c2cc(-c3c4ccccc4c(-c4ccc5c(c4)c4ccccc4n5C)c4c3cnc3ccccc34)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR3 P46089 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TLR7 Q9NYK1 2/20 0.39
▸ GABRP O00591 2/20 0.39
▸ GABRD O14764 2/20 0.39
▸ GABRA1 P14867 2/20 0.39
▸ GABRB1 P18505 2/20 0.39
▸ GABRG2 P18507 2/20 0.39
▸ GABRB3 P28472 2/20 0.39
▸ GABRA5 P31644 2/20 0.39
▸ GABRA3 P34903 2/20 0.39
▸ GABRA2 P47869 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103329 0.85 L3MBTL1 (0.45) KDM4EMAPTALDH1A1MEN1HTT
SCHEMBL1103422 0.83 L3MBTL1 (0.43) KDM4EMAPTALDH1A1MEN1HTT
SCHEMBL1103336 0.82 CDK4 (0.39) GPR3KDM4EMAPTALDH1A1HPGD
SCHEMBL12721945 0.81 GPR3 (0.64) GPR3KDM4EMAPTALDH1A1HPGD
SCHEMBL1103265 0.78 NPC1 (0.50) GPR3KDM4EMAPTALDH1A1HPGD
SCHEMBL1103449 0.77 ESR1 (0.42) GPR3KDM4EMAPTALDH1A1HPGD
SCHEMBL1103479 0.77 ESR1 (0.42) GPR3KDM4EMAPTALDH1A1HPGD
SCHEMBL1103486 0.77 ESR1 (0.42) GPR3KDM4EMAPTALDH1A1HPGD
SCHEMBL1103491 0.77 ESR1 (0.42) GPR3KDM4EMAPTALDH1A1HPGD
SCHEMBL1103452 0.76 KDM4E (0.43) GPR3KDM4EMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 GPR3 1503/4885KDM4E 3367/4885MAPT 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.